Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03040011 |
Recruitment Status :
Completed
First Posted : February 1, 2017
Results First Posted : March 9, 2020
Last Update Posted : March 9, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
To test the hypothesis that preoperative injections along the levator ani muscles and pudendal nerve with bupivacaine and dexamethasone improve pain control after vaginal apical reconstructive surgery. A three-arm, double-blinded, randomized controlled trial of a total of 75 women will be performed.
The study population will be adult women (>18 years of age) with uterovaginal or vaginal vault prolapse who have been scheduled for native tissue vaginal reconstructive surgery which includes an apical support procedure. Participants will be enrolled prior to surgery. The procedure will involved four injection sites: the bilateral levator ani muscles via a transobturator approach and bilateral pudendal nerves via a transvaginal approach. Random assignment will occur to one of three study arms: combined arm (20 milliliters bupivacaine/dexamethasone solution divided between the 4 injection sites), bupivacaine arm (20 milliliters bupivacaine divided between the 4 injection sites), or placebo arm (20 milliliters saline divided between the 4 injection sites).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pelvic Organ Prolapse Surgery Postoperative Pain | Drug: Dexamethasone Drug: Bupivacaine Procedure: Bilateral Pudendal Nerve Block Procedure: Bilateral Levator Ani Muscle Injection Drug: Saline | Phase 1 Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 79 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Three-arm, double-blinded, placebo-controlled, randomized controlled trial |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Double-blinded |
Primary Purpose: | Treatment |
Official Title: | Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block With Bupivacaine and Dexamethasone for Improved Pain Control After Vaginal Reconstructive Surgery: A Three-Arm Randomized Controlled Trial |
Actual Study Start Date : | June 1, 2017 |
Actual Primary Completion Date : | April 11, 2019 |
Actual Study Completion Date : | August 5, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Bupivacaine/Dexamethasone Arm
After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of a mixture of 20 milliliters of 0.25% bupivacaine (2.5mg/milliliter ) and 2 milliliters of dexamethasone (4mg/milliliter). The total amount of the bupivacaine/dexamethasone solution will be divided equally between the four injection sites.
|
Drug: Dexamethasone
Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Other Name: Decadron Drug: Bupivacaine Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Other Name: Marcaine Procedure: Bilateral Pudendal Nerve Block Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side. Procedure: Bilateral Levator Ani Muscle Injection Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract. |
Active Comparator: Bupivacaine Arm
After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.25% bupivacaine (2.5mg/milliliter). The total amount will be divided equally between the four injection sites.
|
Drug: Bupivacaine
Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Other Name: Marcaine Procedure: Bilateral Pudendal Nerve Block Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side. Procedure: Bilateral Levator Ani Muscle Injection Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract. |
Placebo Comparator: Placebo Arm
After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.9% saline (normal saline). The total amount will be divided equally between the four injection sites.
|
Procedure: Bilateral Pudendal Nerve Block
Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side. Procedure: Bilateral Levator Ani Muscle Injection Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract. Drug: Saline Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Other Name: Normal Saline |
- Primary Postoperative Pain Measured by the Numerical Rating Scale (NRS) [ Time Frame: 24 hours postoperatively ]Postoperative pain measured by the numerical rating scale (NRS) at 24 hours postoperatively. The Numeric Rating Scale is an 11 point scale ranging from 0-10 with higher scores indicating worse pain.
- 6 Hour Postoperative Pain Measured by the NRS [ Time Frame: 6 hours postoperatively ]
Postoperative pain as measured by the NRS at 6 hours after surgery. The Numeric Rating Scale is an 11 point scale ranging from 0-10 with higher scores indicating worse pain.
Of note, there is a typographical error in the protocol section and refers to this outcome as a NRS score at 3 hours postoperatively. The final IRB approved protocol is a 6 hour postoperative timepoint and this is the correct outcome reported here in the results section.
- POD 2 Postoperative Pain Measured by the NRS [ Time Frame: 2 days after surgery ]Postoperative Pain Measured by the NRS 2 days after surgery. The Numeric Rating Scale is an 11 point scale ranging from 0-10 with higher scores indicating worse pain.
- POD 3 Postoperative Pain Measured by the NRS [ Time Frame: 3 days after surgery ]Postoperative Pain Measured by the NRS 3 days after surgery. The Numeric Rating Scale is an 11 point scale ranging from 0-10 with higher scores indicating worse pain.
- 1 Week Postoperative Pain Measured by the NRS [ Time Frame: 1 week after surgery ]Postoperative Pain Measured by the Numeric Rating Scale 1 week after surgery. The Numeric Rating Scale is an 11 point scale ranging from 0-10 with higher scores indicating worse pain.
- Proportion of Patients With Same Day Discharge [ Time Frame: Day of surgery ]Same day discharge was defined as a patient being discharged on the same day as surgery and did not require an admission after surgery. The proportion of patients who were discharged on the day of surgery was compared between groups.
- Postoperative Urinary Retention [ Time Frame: 0-24 hours postoperatively ]Urinary retention was defined as the need to perform self-catheterization or have an indwelling catheter placed postoperatively. The proportion of patients with urinary retention was compared between groups.
- Adverse Events [ Time Frame: 0-12 weeks postoperatively ]The number of adverse events in each study group was assessed and compared between study groups. An adverse event was described as any medical or surgical complication that occurred either intraoperatively or postoperatively.
- Nausea and Vomiting Measured by the PONV Scale [ Time Frame: 6 hours postoperatively ]Intensity of postoperative nausea and vomiting (PONV) measured by the PONV scale prior to discharge. The Postoperative Nausea and Vomiting Intensity Scale is a four-question assessment to measure clinically significant nausea and vomiting with a range from 0-7 with higher scores signifying more clinically significant nausea and vomiting.
- Anti-emetic Consumption [ Time Frame: 3 hours postoperatively ]The amount of inpatient anti-emetic consumption, recorded in number of doses of nausea medication
- Return to Baseline Activities Using the Activities Assessment Scale [ Time Frame: 1 week postoperative ]
Resumed normal daily activities using the Activities Assessment Scale (AAS) by 1 week after surgery. The AAS is a 13-point scale on which patients rate their difficulty performing a range of activities from "No difficulty" to "Not able to do it." A final score ranging from 0-100 is transformed, with higher numbers reflecting less difficulty with activities.
We defined return to normal as when a patient's postoperative AAS scores was at or greater than the baseline AAS score. We report the proportion of patients in each study arm who returned to baseline activity at each timepoint.
- Return to Baseline Activities Using the Activities Assessment Scale [ Time Frame: 2 week postoperative ]
Resumed normal daily activities using the Activities Assessment Scale (AAS) by 2 weeks after surgery. The AAS is a 13-point scale on which patients rate their difficulty performing a range of activities from "No difficulty" to "Not able to do it." A final score ranging from 0-100 is transformed, with higher numbers reflecting less difficulty with activities.
We defined return to normal as when a patient's postoperative AAS scores was at or greater than the baseline AAS score. We report the proportion of patients in each study arm who returned to baseline activity at each timepoint.
- Return to Baseline Activities Using the Activities Assessment Scale [ Time Frame: 6 weeks postoperative ]
Resumed normal daily activities using the Activities Assessment Scale (AAS) by 6 weeks after surgery. The AAS is a 13-point scale on which patients rate their difficulty performing a range of activities from "No difficulty" to "Not able to do it." A final score ranging from 0-100 is transformed, with higher numbers reflecting less difficulty with activities.
We defined return to normal as when a patient's postoperative AAS scores was at or greater than the baseline AAS score. We report the proportion of patients in each study arm who returned to baseline activity at each timepoint.
- Return to Baseline Activities Using the Activities Assessment Scale [ Time Frame: 12 weeks postoperative ]
Resumed normal daily activities using the Activities Assessment Scale (AAS) by 12 weeks after surgery. The AAS is a 13-point scale on which patients rate their difficulty performing a range of activities from "No difficulty" to "Not able to do it." A final score ranging from 0-100 is transformed, with higher numbers reflecting less difficulty with activities.
We defined return to normal as when a patient's postoperative AAS scores was at or greater than the baseline AAS score. We report the proportion of patients in each study arm who returned to baseline activity at each timepoint.
- POD 1 Narcotic Consumption [ Time Frame: Postoperative day 1 ]The total amount of narcotic pain medication used on postoperative day 1 was calculated and measured in oral morphine equivalents.
- POD 2 Narcotic Consumption [ Time Frame: Postoperative day 2 ]The total amount of narcotic pain medication used on postoperative day 2 was calculated and measured in oral morphine equivalents.
- POD 3 Narcotic Consumption [ Time Frame: Postoperative day 3 ]The total amount of narcotic pain medication used on postoperative day 3 was calculated and measured in oral morphine equivalents.
- POD 1 Ibuprofen Consumption [ Time Frame: Postoperative day 1 ]The total amount of ibuprofen medication used on postoperative day 1.
- POD 2 Ibuprofen Consumption [ Time Frame: Postoperative day 2 ]The total amount of ibuprofen medication used on postoperative day 2.
- POD 3 Ibuprofen Consumption [ Time Frame: Postoperative day 3 ]The total amount of ibuprofen medication used on postoperative day 3.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Women ages 18 or older who are scheduled for a vaginal native tissue repair with apical support procedure including uterosacral ligament suspension, sacrospinous ligament fixation, or colpectomy and colpocleisis with or without levator myorrhaphy
- Concomitant procedures including hysterectomy, anterior and posterior colporrhaphies , perineorrhaphies and midurethral sling placements are acceptable and do not result in exclusion
- Available for at least 12 weeks of follow-up
- Able to undergoing general anesthesia
Exclusion Criteria:
- Planned mesh-augmented apical support procedure (placement of synthetic midurethral sling is acceptable and not considered an exclusion criteria)
- Planned mesh excision
- Laparoscopic, robotic or abdominal surgery
- Known adverse reaction or allergy to intervention medication
- Evidence of fistula or known infection (vulvovaginal cellulitis, abscess, abdominopelvic infection, or systemic fungal infection)
- Chronic pelvic pain as an active issue
- Daily opiate consumption for any indication
- History of pelvic radiation
- Chronic steroid use
- Diabetes mellitus
- Known HIV/AIDS or immunosuppression secondary to transplant related medications
- Planned surgery under regional anesthesia
- Non-English speaking or inability to complete questionnaires
- Bleeding disorders that would impair a patient's clotting ability
- Weight less than 50kg

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03040011
United States, Pennsylvania | |
Magee-Womens Hospital of UPMC | |
Pittsburgh, Pennsylvania, United States, 15213 |
Principal Investigator: | Lauren Giugale, MD | University of Pittsburgh |
Documents provided by Lauren Giugale, MD, University of Pittsburgh:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Lauren Giugale, MD, MD, University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT03040011 |
Other Study ID Numbers: |
PRO16110378 |
First Posted: | February 1, 2017 Key Record Dates |
Results First Posted: | March 9, 2020 |
Last Update Posted: | March 9, 2020 |
Last Verified: | March 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Vaginal Surgery Pelvic Organ Prolapse Postoperative Pain |
Pain, Postoperative Prolapse Pelvic Organ Prolapse Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Pathological Conditions, Anatomical Dexamethasone Bupivacaine Anti-Inflammatory Agents Antiemetics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Anesthetics, Local Anesthetics Central Nervous System Depressants Sensory System Agents |